Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: A report of 10 cases

American Journal of Kidney Diseases

Volumn 64, Issue 4, 2014, Pages 633-637

  Ardissino, Gianluigi ^a   Testa, Sara ^a   Possenti, Ilaria ^a   Tel, Francesca ^a   Paglialonga, Fabio ^a   Salardi, Stefania ^a   Tedeschi, Silvana ^a   Belingheri, Mirco ^a   Cugno, Massimo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Atypical hemolytic uremic syndrome; discontinuation; eculizumab

Indexed keywords

ECULIZUMAB; HEMOGLOBIN; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMOLYTIC UREMIC SYNDROME; HOME MONITORING; HUMAN; MAINTENANCE THERAPY; MALE; MENINGITIS; QUALITY OF LIFE; RELAPSE; REMISSION; ADOLESCENT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CASE REPORT; CLASSIFICATION; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; HEMOGLOBINURIA; INFANT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PRESCHOOL CHILD; PROCEDURES; PSYCHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINALYSIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; CHILD, PRESCHOOL; COMPLEMENT INACTIVATING AGENTS; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMOGLOBINURIA; HUMANS; INFANT; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; QUALITY OF LIFE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; URINALYSIS; WITHHOLDING TREATMENT;

EID: 84908098893     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.01.434     Document Type: Article

References (32)

1. D. Kavanagh, A. Richards, and J. Atkinson Complement regulatory genes and hemolytic uremic syndromes Annu Rev Med 59 2008 293 309
2. C.J. Mache, B. Acham-Roschitz, and V. Frémeaux-Bacchi Complement inhibitor eculizumab in atypical hemolytic uremic syndrome Clin J Am Soc Nephrol 4 8 2009 1312 1316
3. V. Châtelet, T. Lobbedez, V. Frémeaux-Bacchi, M. Ficheux, J.P. Ryckelynck, and B. Hurault de Ligny Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report Transplant Proc 42 10 2010 4353 4355
4. J. Scheiring, A. Rosales, and L.B. Zimmerhackl Clinical practice. Today's understanding of the haemolytic uraemic syndrome Eur J Pediatr 169 1 2010 7 13
5. A.R. Constantinescu, M. Bitzan, and L.S. Weiss Non-enteropathic hemolytic uremic syndrome: causes and short-term course Am J Kidney Dis 43 6 2004 976 982
6. C.M. Taylor, S. Machin, S.J. Wigmore, T.H. Goodship Working Party From the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom Br J Haematol 148 1 2010 37 47
7. L. Rees Atypical HUS: time to take stock of current guidelines and outcome measures? Pediatr Nephrol 28 5 2013 675 677
8. M. Ohanian, C. Cable, and K. Halka Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report Clin Pharmacol 3 2011 45 50
9. I. Moore, L. Strain, and I. Pappworth Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome Blood 115 2 2010 379 387
10. M. Delvaeye, M. Noris, and A. De Vriese Thrombomodulin mutations in atypical hemolytic-uremic syndrome N Engl J Med 361 4 2009 345 357
11. D. Kavanagh, and T.H. Goodship Atypical hemolytic uremic syndrome Curr Opin Hematol 17 5 2010 432 438
12. C. Skerka, M. Józsi, P.F. Zipfel, M.A. Dragon-Durey, and V. Fremeaux-Bacchi Autoantibodies in haemolytic uraemic syndrome (HUS) Thromb Haemost 101 2 2009 227 232
13. V. Fremeaux-Bacchi Treatment of atypical uremic syndrome in the era of eculizumab Clin Kidney J 5 2012 4 6
14. N. Besbas, B. Gulhan, and D. Karpman Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab Pediatr Nephrol 28 1 2013 155 158
15. O. Köse, L.B. Zimmerhackl, T. Jungraithmayr, C. Mache, and J. Nürnberger New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab Semin Thromb Hemost 36 6 2010 669 672
16. FDA. News release September 23, 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm272990.htm. Accessed March 13, 2014.
17. J. Zuber, M. Le Quintrec, R. Sberro-Soussan, C. Loirat, V. Frémeaux-Bacchi, and C. Legendre New insights into postrenal transplant hemolytic uremic syndrome Nat Rev Nephrol 7 1 2011 23 35
18. R.A. Gruppo, and R.P. Rother Eculizumab for congenital atypical hemolytic-uremic syndrome N Engl J Med 360 5 2009 544 546
19. J. Nürnberger, T. Philipp, and O. Witzke Eculizumab for atypical hemolytic-uremic syndrome N Engl J Med 360 5 2009 542 544
20. R. Vilalta, E. Lara, and A. Madrid Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome Pediatr Nephrol 27 12 2012 2323 2326
21. European Medicines Agency. Soliris (online). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000791/human-med-001055.jsp&mid=WC0b01ac058001d24 (2012). Accessed March 13, 2014.
22. R. Carr, and S.R. Cataland Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation Ann Hematol 92 6 2013 845 846
23. C.J. Mache, B. Acham-Roschitz, and V. Fremeaux-Bacchi Complement inhibitor eculizumab in atypical hemolytic uremic syndrome Clin J Am Soc Nephrol 4 8 2009 1312 1316
24. J. Zuber, M. Le Quintrec, R. Sberro-Soussan, C. Loirat, V. Fremeaux-Bacchi, and C. Legendre New insights into post-renal transplant hemolytic uremic syndrome Nat Rev Nephrol 7 1 2011 23 35
25. F.S. Cayci, N. Cakar, V.S. Hancer, N. Uncu, B. Acar, and G. Gur Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation Pediatr Nephrol 27 12 2012 2327 2331
26. K. Gulleroglu, K. Fidan, V.S. Hançer, U. Bayrakci, E. Baskin, and O. Soylemezoglu Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab Pediatr Nephrol 28 5 2013 827 830
27. G.H. Struijk, A.H. Bouts, G.T. Rijkers, E.A. Kuin, I.J. ten Berge, and F.J. Bemelman Meningococcal sepsis complicating eculizumab treatment despite prior vaccination Am J Transplant 13 3 2013 819 820
28. S. Ram, L.A. Lewis, and P.A. Rice Infections of people with complement deficiencies and patients who have undergone splenectomy Clin Microbiol Rev 23 2010 740 780
29. G. Ariceta, N. Besbas, S. Johnson European Paediatric Study Group for HUS Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome Pediatr Nephrol 24 4 2009 687 696
30. J. Zuber, F. Fakhouri, L.T. Roumenina, C. Loirat, V. Frémeaux-Bacchi French Study Group for aHUS/C3G Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat Rev Nephrol 8 11 2012 643 657
31. C. Loirat, and V. Frémeaux-Bacchi Atypical hemolytic uremic syndrome Orphanet J Rare Dis 6 2011 60
32. J. Zuber, M. Le Quintrec, S. Krid French Study Group for Atypical HUS Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation Am J Transplant 12 12 2012 3337 3354